For the fourth consecutive year, Boston Scientific is recognized as a Derwent Top 100 Global Innovator™ by Clarivate Analytics. The annual report highlights the world’s most innovative organizations for research and development, protection of intellectual property and the achievement of commercial success.
In 2019, Boston Scientific invested approximately $1 billion in research and development and launched 87 new products. The company’s full portfolio offers more than 13,000 products that improve outcomes, reduce costs, increase efficiencies and – most importantly – help treat 30 million patients each year.
The LOTUS Edge™ Aortic Valve System, approved by the FDA in Spring of 2019, is one example of how Boston Scientific approaches innovation to help patients live longer, healthier lives. The LOTUS Edge valve is a transcatheter aortic valve replacement (TAVR) technology that is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement via open heart surgery.
The team behind the LOTUS Edge valve saw an opportunity to provide a more controlled and predictable procedure, and as a result, created a device that can help treat more patients in more clinical scenarios.
See their full story here:
The Derwent Top 100 Global Innovators methodology analyzes patent and citation data across four main criteria: patent volume, application-to-grant success, globalization and citation influence (how often a patent is cited by other companies in the patenting of their inventions). This year’s listing of global innovators includes companies from three continents and 14 countries/regions. Click here for more information on the report.
* LOTUS Edge is a transcatheter aortic valve replacement (TAVR) technology that is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement via open heart surgery.